Thermo Fisher announces US$2B investment in U.S. operations

USA—Thermo Fisher Scientific, a leading Massachusetts-based producer of medical instruments, diagnostics, and pharmaceuticals, has announced plans to invest an additional US$2 billion in its U.S. operations over the next four years.

This decision comes amid growing uncertainty in the global trade environment, particularly as the Trump administration’s tariffs have prompted many biopharma companies to reinforce their American presence.

The company’s investment will be divided into two main areas: US$1.5 billion will be allocated to expanding and enhancing its U.S. manufacturing operations, while the remaining US$500 million will support research and development (R&D) initiatives.

This move is intended to strengthen American innovation, manufacturing, and economic competitiveness, especially in the life sciences sector.

Thermo Fisher already operates 64 manufacturing sites across 37 states in the U.S., producing analytical instruments, specialty diagnostics, and life sciences solutions.

These facilities also provide contract development and manufacturing services for pharmaceutical innovators.

The new investment will further bolster the company’s capacity to develop and produce medicines domestically, supporting a resilient U.S. healthcare supply chain and generating a strong multiplier effect across the American economy.

CEO Marc Casper highlighted the strategic significance of this commitment, asserting that their dedication to U.S. manufacturing reflects their confidence in America’s continued leadership in science and innovation.

He added that by expanding their U.S. operations, they ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come.

This announcement aligns Thermo Fisher with a broader trend among major biopharma companies, such as Roche, Johnson & Johnson, Eli Lilly, and Novartis, all of which have recently unveiled significant U.S.-centered investment plans.

The current climate of tariff threats and trade policy changes has made importing into the U.S. less attractive, prompting companies to boost domestic operations to offset potential impacts on their supply chains and costs.

Thermo Fisher’s global footprint remains extensive, with operations in 43 countries and a workforce of approximately 125,000 employees worldwide, including more than 50,000 in the U.S.

The company’s revenue has more than doubled in recent years, increasing from US$21 billion in 2017 to US$43 billion last year.

This growth reflects both its expansion and its escalating investment in American innovation and manufacturing.

Looking ahead, Thermo Fisher’s US$2 billion investment is expected to create high-paying jobs, expand manufacturing and laboratory services, and drive further advancements in research and development.

This strategic move not only ensures the continued production of life-saving medicines in the U.S., but also reinforces America’s leadership in science and technology for years to come.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.